Tandem Diabetes Care (TNDM) FCF Margin Growth (3y) (2016 - 2026)

Tandem Diabetes Care (TNDM) FCF Margin Growth (3y) (2016 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) FCF Margin Growth (3y) (Qtr)
1 Abbott Laboratories 201.40 Bn 194.75 Bn 6.27 Bn 38.00
2 Stryker 122.29 Bn 119.41 Bn 3.81 Bn 30.00
3 Medtronic 105.01 Bn 96.40 Bn 6.41 Bn -310.00
4 Boston Scientific 64.81 Bn 63.59 Bn 3.61 Bn 96.00
5 Edwards Lifesciences 55.28 Bn 51.60 Bn 1.29 Bn -2,196.00
6 Dexcom 29.06 Bn 27.94 Bn 750.30 Mn 2,679.00
7 Koninklijke Philips 29.02 Bn 25.93 Bn 2.07 Bn -20.00
8 GE HealthCare Technologies 28.27 Bn 26.20 Bn 1.98 Bn -472.00
9 Smith & Nephew 25.80 Bn 25.22 Bn - -
10 Tandem Diabetes Care 1.16 Bn 587.46 Mn 136.79 Mn 1,797.00

Historic Data

Download Data
DateValue
Mar 31, 2026 1,797.00
Dec 31, 2025 -146.00
Sep 30, 2025 -1,342.00
Jun 30, 2025 -627.00
Mar 31, 2025 -1,658.00
Dec 31, 2024 89.00
Sep 30, 2024 -1,018.00
Jun 30, 2024 -2,255.00
Mar 31, 2024 -2,618.00
Dec 31, 2023 -1,117.00
Sep 30, 2023 1,439.00
Jun 30, 2023 -2,648.00
Mar 31, 2023 1,195.00
Dec 31, 2022 -918.00
Sep 30, 2022 61.00
Jun 30, 2022 -41.00
Mar 31, 2022 1,396.00
Dec 31, 2021 -1,234.00
Sep 30, 2021 2,867.00
Jun 30, 2021 3,808.00